Rhofade, Oxymetazoline Cream 1% for the redness of Rosacea
Rhofade is Allergan’s Oxymetazoline based topical treatment for the red face of rosacea. Rhofade is known chemically as a Selective α1-Adrenergic Receptor Agonist, and during the drug’s development was known as AGN-199201 and also V-101.
Recent Rosacea Blog Posts
Allergan has announced the availability of the Rhofade Cream Savings Program, which is promoted as allowing access to a prescription of Rhofade for as little as $35. This out-of-pocket amount only applies if you have commercial insurance that covers Rhofade. If your insurance does not cover Rhofade `you may pay as little as $75′. The […]
Allergan’s Oxymetazoline based cream, Rhofade (oxymetazoline hydrochloride cream 1%) – for the treatment of the redness of rosacea is now generally available. Does it work to effectively and safely reduce the redness of rosacea? You have come to the right page to find out. Some Oxymetazoline History For rosacea sufferers it has been a long […]
The official web site for Rhofade has gone live and now contains information that Allergan has not previously made public. Official web sites for prescription products normally contain statistics summarising clinical trial data, official dosage information, and other notes for doctors wanting to understand the cost and benefit of a new treatment. For rosacea sufferers, […]
So RHOFADE has been approved by the FDA and will be available in the United States from May 2017. What does the published trial data suggest about the likelihood of RHOFADE being a winning treatment for your red face?Two clinical trials comparing RHOFADE to an inactive gel produced similar results, so rosacea sufferers can have some […]
Good news to start 2017, and as predicted, the FDA has approved Allergan’s RHOFADE. Yes they are going to use uppercase and scream RHOFADE at us everytime we see the product name. Allergan says that RHOFADE will be available for commercial supply starting May 2017 in the United States. Allergan Announces FDA Approval Of RHOFADE […]